- Home
- FATE vs HEQ Comparison
FATE vs HEQ Comparison
Compare FATE & HEQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FATE
- HEQ
- Stock Information
- Founded
- FATE 2007
- HEQ 2011
- Country
- FATE United States
- HEQ United States
- Employees
- FATE N/A
- HEQ N/A
- Industry
- FATE Biotechnology: Biological Products (No Diagnostic Substances)
- HEQ Investment Managers
- Sector
- FATE Health Care
- HEQ Finance
- Exchange
- FATE Nasdaq
- HEQ Nasdaq
- Market Cap
- FATE 130.7M
- HEQ 127.8M
- IPO Year
- FATE 2013
- HEQ N/A
- Fundamental
- Price
- FATE $1.07
- HEQ $10.38
- Analyst Decision
- FATE Hold
- HEQ
- Analyst Count
- FATE 7
- HEQ 0
- Target Price
- FATE $3.83
- HEQ N/A
- AVG Volume (30 Days)
- FATE 1.4M
- HEQ 43.1K
- Earning Date
- FATE 08-12-2025
- HEQ 01-01-0001
- Dividend Yield
- FATE N/A
- HEQ 9.78%
- EPS Growth
- FATE N/A
- HEQ N/A
- EPS
- FATE N/A
- HEQ N/A
- Revenue
- FATE $13,335,000.00
- HEQ N/A
- Revenue This Year
- FATE N/A
- HEQ N/A
- Revenue Next Year
- FATE N/A
- HEQ N/A
- P/E Ratio
- FATE N/A
- HEQ N/A
- Revenue Growth
- FATE 105.85
- HEQ N/A
- 52 Week Low
- FATE $0.66
- HEQ $9.08
- 52 Week High
- FATE $5.49
- HEQ $11.84
- Technical
- Relative Strength Index (RSI)
- FATE 40.63
- HEQ 37.42
- Support Level
- FATE $1.19
- HEQ $10.45
- Resistance Level
- FATE $1.35
- HEQ $10.68
- Average True Range (ATR)
- FATE 0.08
- HEQ 0.07
- MACD
- FATE -0.01
- HEQ -0.02
- Stochastic Oscillator
- FATE 3.45
- HEQ 6.25
About FATE Fate Therapeutics Inc.
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.
About HEQ John Hancock Hedged Equity & Income Fund of Beneficial Interest
John Hancock Hedged Equity & Income Fund is a closed-end management investment company. Its investment objective is to provide total return with a focus on current income and gains and also consisting of long-term capital appreciation. It invests in various sectors such as financials, consumer discretionary, information technology, energy, healthcare, materials, real estate, consumer staples, short-term investments, and others.